Kezar Life Sciences News

Hold Rating on Kezar Life Sciences Amid Trial Progress and Efficacy Concerns

TipRanksMay 10 18:37

Kezar Life Sciences Q1 EPS $(0.30) Beats $(0.33) Estimate

Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 3.23 percent increase over losses of $(0

BenzingaMay 10 04:40

Kezar Life Sciences | 10-Q: Quarterly report

Futu NewsMay 10 04:16 · Announcements

Press Release: Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update -- PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis act

Dow JonesMay 10 04:01

Kezar Life Sciences 1Q Loss $21.7M >KZR

Kezar Life Sciences 1Q Loss $21.7M >KZR

Dow JonesMay 10 04:01

13 Best Penny Stocks to Buy According to Billionaire Ken Griffin

Yahoo FinanceApr 9 05:38

Analysts' Opinions Are Mixed on These Healthcare Stocks: Kezar Life Sciences (KZR), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Cue Health (HLTH)

TipRanksMar 25 20:20

Kezar Life Sciences: KZR-261 Dose Escalation Study Currently Enrolling 9th Cohort>KZR

Kezar Life Sciences: KZR-261 Dose Escalation Study Currently Enrolling 9th Cohort>KZR

Dow JonesMar 15 04:06

Kezar Life Sciences Q4 EPS $(0.44) Misses $(0.38) Estimate

Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.38) by 15.79 percent. This is a 76 percent decrease over losses of $(

BenzingaMar 15 04:04

Kezar Life Sciences Still Expects Topline Data From Lupus Nephritis Treatment Trial In Mid-2026>KZR

Kezar Life Sciences Still Expects Topline Data From Lupus Nephritis Treatment Trial In Mid-2026>KZR

Dow JonesMar 15 04:04

Kezar Life Sciences 4Q Loss/Shr 44c >KZR

Kezar Life Sciences 4Q Loss/Shr 44c >KZR

Dow JonesMar 15 04:01

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the

BusinesswireMar 9 05:05

Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief

BusinesswireFeb 29 05:01

Reported Late Monday, Everest Medicines And Kezar Life Sciences Received IND Approval From China's NMPA For The PALIZADE Trial In Lupus Nephritis

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (NASDAQ:KZR) announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approve

BenzingaFeb 27 16:13

Everest Medicines and Kezar Life Sciences Receive IND Approval From China NMPA for PALIZADE Trial in Lupus Nephritis

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China's...

PR NewswireFeb 27 07:10

As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits

The lithium market is facing persistent turmoil as spot prices have continuously declined for more than a year. Supply shortages and speculation caused a lithium bubble in 2022, with spot prices reach

BenzingaJan 9 01:20

Analysts' Top Healthcare Picks: DocGo (DCGO), Kezar Life Sciences (KZR)

TipRanksDec 4, 2023 19:30

Analyst Expectations for Kezar Life Sciences's Future

Analysts have provided the following ratings for Kezar Life Sciences (NASDAQ:KZR) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings30100Last 30D100001M Ag

BenzingaNov 27, 2023 22:00

HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $20 price target.

BenzingaNov 27, 2023 20:03

Buy Rating Affirmed: Kezar Life Sciences' Promising Trials and Strong Financials

Kezar Life Sciences (KZR), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright remains neutral on the stock and has a $20.00 price target.

TipRanksNov 27, 2023 19:26